D. Baldwin

发表

Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders? A Conceptual Framework

I. Glick, A. Altamura, B. Dell’Osso, 2012, Psychopathology.

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

D. Nutt, N. Fineberg, S. Chamberlain, 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) as an overall indicator of population mental health and well-being in the UK veterinary profession.

D. Baldwin, G. Yadegarfar, J. Sinclair, 2011, Veterinary journal.

The treatment of sleep disorders.

D. Baldwin, R. Priest, N. Smeyatsky, 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability

D. Baldwin, M. Garner, Nicholas Hedger, 2015, Neuroscience & Biobehavioral Reviews.

Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics

D. Nutt, N. Fineberg, K. Domschke, 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Paul McCrone, Hans-Ulrich Wittchen, Naomi Fineberg, 2014, Journal of psychopharmacology.

Psychiatry should not become hostage to placebo: An alternative interpretation of antidepressant–placebo differences in the treatment response in depression

D. Baldwin, Z. Rihmer, X. Gonda, 2012, European Neuropsychopharmacology.

Research in anxiety disorders: From the bench to the bedside

D. Stein, D. Baldwin, M. Garner, 2009, European Neuropsychopharmacology.

Descriptions of the depressive disorders

D. Baldwin, J. Birtwistle, 2002 .

Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review

D. Baldwin, D. Kingdon, F. Howells, 2017, Human psychopharmacology.

Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo

B. Rothbaum, D. Stein, J. Davidson, 2012, Journal of psychopharmacology.

Development and evaluation of psychotropic drugs

D. Baldwin, K. Ajel, 2007 .

A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder

Dan J Stein, Leonardo Franklin Fontenelle, M. Stein, 2010, Current psychiatry reports.

Escitalopram: efficacy and tolerability in the treatment of depression.

D. Baldwin, David S Baldwin, 2002, Hospital medicine.

Title: Subjective sleep, depression and anxiety: inter-relationships in a non-clinical sample Short running title: Subjective sleep, depression and anxiety Authors

D. Baldwin, A. Mayers, Christina Campbell, 2011 .

Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?

D. Baldwin, D. Kingdon, F. Howells, 2016, Human psychopharmacology.

Depression and sexual function

D. Baldwin, 1996 .

Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety.

F. Coppedè, C. Martini, D. Baldwin, 2017, Journal of affective disorders.

Anxiety symptom severity and functional recovery or relapse.

Dan J Stein, D. Baldwin, O. Dolberg, 2009, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Dysthymia: Options in Pharmacotherapy

D. Baldwin, S. Rudge, Sally C Thomas, 1995 .

Potential neuroimmunological targets in the treatment of anxiety disorders.

D. Baldwin, R. Hou, Zhen Tang, 2013, Modern trends in pharmacopsychiatry.

A neuroimmunological perspective on anxiety disorders

D. Baldwin, R. Hou, 2012, Human psychopharmacology.

Escitalopram Therapy for Major Depression and Anxiety Disorders

E. Weiller, D. Baldwin, E. Reines, 2007, The Annals of pharmacotherapy.

Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom

Dan J Stein, D. Baldwin, M. Hemels, 2006, The Annals of pharmacotherapy.

Use of licensed medicines for unlicensed applications in psychiatric practice

Paul J. Harrison, A. Young, O. Howes, 2017 .

Off-label prescribing in psychiatric practice

D. Baldwin, N. Kosky, 2007 .

Pharmacological Treatment of Generalized Anxiety Disorder (GAD)

D. Baldwin, 2020 .

Overcoming challenges in the management of schizophrenia.

D. Baldwin, L. Kopala, P. Widén, 1999, International journal of psychiatry in clinical practice.

An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder

S. Pallanti, D. Baldwin, C. Allgulander, 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Escitalopram in the treatment of generalized anxiety disorder

D. Baldwin, R. Nair, 2005, Expert review of neurotherapeutics.

The Overlap of Obsessive-Compulsive Disorder and Social Phobia and its Treatment

D. Baldwin, D. Meron, Emma K. Brandish, 2008, CNS Spectrums.

Role of pregabalin in the treatment of generalized anxiety disorder

D. Baldwin, K. Ajel, 2007, Neuropsychiatric disease and treatment.

Benzodiazepines: Risks and benefits. A reconsideration

D. Nutt, B. Leonard, K. Aitchison, 2013, Journal of psychopharmacology.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

N. Fineberg, D. Baldwin, G. Barton, 2018, International clinical psychopharmacology.

Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study

D. Baldwin, M. Garner, A. Darekar, 2020, The international journal of neuropsychopharmacology.

Interventions with potential to improve the mental health and wellbeing of UK veterinary surgeons

D. Baldwin, J. Sinclair, D. Bartram, 2010, Veterinary Record.

Psychosocial working conditions and work-related stressors among UK veterinary surgeons.

D. Baldwin, G. Yadegarfar, D. Bartram, 2009, Occupational medicine.

The roles of a psychiatrist in the COVID-19 pandemic

D. Baldwin, Robert Gordon, K. Marlowe, 2021, Clinics in Integrated Care.

What is the role of a psychiatrist in the COVID-19 pandemic?

D. Baldwin, 2020, Medicine.

Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis

D. Baldwin, R. Hou, Lan-fen Liu, 2019, Brain, Behavior, and Immunity.

A systematic review of specialist inpatient dementia care services versus standard inpatient dementia care in acute hospitals

D. Baldwin, H. Patel, V. Osman-Hicks, 2018, Aging Clinical and Experimental Research.

Cancer, Benign Gynecology, and Sexual Function--Issues and Answers.

D. Baldwin, K. McVary, G. Hackett, 2016, The journal of sexual medicine.

The need for long-term treatment of depression

D. Baldwin, J. Birtwistle, 2002 .

Unmet needs in the pharmacological management of depression

D. Baldwin, 2001, Human psychopharmacology.

Impact of Substance Use Disorder on Quality of Inpatient Mental Health Services for People With Anxiety and Depression

D. Baldwin, M. Crawford, A. Quirk, 2020, Journal of dual diagnosis.

Non-pharmacological treatment

K. Domschke, D. Baldwin, B. Bandelow, 2013 .

Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis.

Dan J Stein, B. Rothbaum, J. Davidson, 2009, The international journal of neuropsychopharmacology.

Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study

D. Baldwin, A. Quirk, R. Sanatinia, 2021, BMC Psychiatry.

Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”

D. Baldwin, J. Sinclair, Sophia E Chambers, 2016, Drug Safety.

Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discovery

Dan J Stein, D. Baldwin, M. Breen, 2016, Human psychopharmacology.

What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

D. Stein, D. Baldwin, O. Dolberg, 2006, The Journal of clinical psychiatry.

Association between Cyclic Meditation and Creative Cognition: Optimizing Connectivity between the Frontal and Parietal Lobes

D. Baldwin, M. Garner, N. Tiwari, 2018 .

Should benzodiazepines still have a role in treating patients with anxiety disorders?

D. Baldwin, Bilal Talat, 2012, Human psychopharmacology.

Prescribing of the antidepressant duloxetine: Can local clinical audit findings facilitate medicines management decisions?

D. Baldwin, K. Ajel, K. Bhogal, 2008, International journal of psychiatry in clinical practice.

Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.

J. A. Boer, D. Nutt, J. Davidson, 1998, The Journal of clinical psychiatry.

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Michael J. Campbell, M. Buxton, D. Baldwin, 2005, Health technology assessment.

Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions

D. Baldwin, C. Hawley, A. Roberts, 1994, International clinical psychopharmacology.

Clinical descriptions of the anxiety disorders

D. Baldwin, J. Birtwistle, 2002 .

Threat reversal learning and avoidance habits in generalised anxiety disorder

B. Sahakian, A. Apergis-Schoute, D. Baldwin, 2022, Translational Psychiatry.

Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines

J. Crolla, P. Jacobs, D. Baldwin, 2003 .

P.3.033 Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines

J. Crolla, P. Jacobs, D. Baldwin, 2003, European Neuropsychopharmacology.

Impact of co-morbid personality disorder on quality of inpatient mental health services for people with anxiety and depression.

D. Baldwin, M. Crawford, A. Quirk, 2020, Personality and mental health.

Relationship of behavioral inhibition to separation anxiety in a sample (N = 377) of adult individuals with mood and anxiety disorders.

K. Domschke, D. Baldwin, M. Abelli, 2022, Comprehensive psychiatry.

The use of antidepressants in clinical practice: focus on agomelatine

D. Baldwin, R. McAllister-Williams, P. Haddad, 2010, Human psychopharmacology.

Use of St John's wort (Hypericum perforatum L) in members of a depression self-help organisation: a 12-week open prospective pilot study using the HADS scale

D. Baldwin, A. Mayers, R. Middleton, 2004 .

The reported use and effectiveness of Hypericum (St John’s wort) on affective symptoms in a depression self-help group

D. Baldwin, A. Mayers, R. Dyson, 2002 .

Coronary Heart Disease, Diabetes, and Sexuality in Men.

D. Baldwin, K. McVary, G. Hackett, 2016, The journal of sexual medicine.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders

D. Rujescu, E. Hollander, N. Fineberg, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Attention-Deficit and Disruptive Behavior Disorders

C. McDougle, D. Posey, C. Buhusi, 2014 .

Reboxetine in the treatment of depression: Early clinical experience in the UK.

E. Szabadi, D. Baldwin, R. Bullock, 1998, International journal of psychiatry in clinical practice.

Attention Deficit Hyperactivity Disorders: Animal Models

C. McDougle, D. Posey, C. Buhusi, 2014 .

Medical cannabis in the UK: From principle to practice

L. Phillips, D. Nutt, D. Baldwin, 2020, Journal of psychopharmacology.

Poor monitoring of physical health in patients referred to a mood disorders service

D. Baldwin, R. Holt, David Lack, 2015, Therapeutic advances in psychopharmacology.

Pharmacotherapy of generalized anxiety disorder.

D. Baldwin, C. Allgulander, 2013, Modern trends in pharmacopsychiatry.

Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review

D. Baldwin, S. Cortese, M. Garner, 2022, The international journal of neuropsychopharmacology.

Alcohol consumption among veterinary surgeons in the UK.

D. Baldwin, J. Sinclair, D. Bartram, 2009, Occupational medicine.

Clomipramine for OCD

N. Fineberg, D. Baldwin, S. Montgomery, 1990, British Journal of Psychiatry.

Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.

D. Baldwin, E. Reines, S. Schmidt, 2022, Journal of affective disorders.

A novel procedure to investigate social anxiety using videoconferencing software: A proof-of-concept study

D. Baldwin, M. Garner, N. Huneke, 2022, Psychiatry Research.

Understanding depression – the ‘black dog’

D. Baldwin, D. Bartram, 2007, In Practice.

Pharmacology for sleep disturbance in PTSD

D. Baldwin, K. Thomas, G. Lipinska, 2016, Human psychopharmacology.

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

D. Baldwin, G. Nomikos, I. Florea, 2016, Journal of psychopharmacology.

Pharmacological treatment of panic disorder.

P. Zwanzger, D. Baldwin, B. Bandelow, 2013, Modern trends in pharmacopsychiatry.

Recurrent brief depression

D. Baldwin, J. Sinclair, 2014 .

The duration, nature and recurrence rate of brief depressions

S. Montgomery, D. Baldwin, Mary Green, 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Task Force on Treatment Guidelines for Bipolar Disorders

H. Möller, G. Goodwin, S. Kasper, 2002 .

Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications.

D. Baldwin, 2021, Addiction.

Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo

Dan J Stein, D. Baldwin, O. Dolberg, 2007, Pharmacopsychiatry.

Importance of sleep disturbance in mood and anxiety disorders

D. Baldwin, 2007 .

HAS RECURRENT BRIEF DEPRESSION A DIFFERENT PHARMACOLOGY

D. Baldwin, S. Montgomery, D. Montgomery, 1992, Clinical neuropharmacology.

Recurrent brief depression – more investigations in clinical samples are now required

D. Baldwin, 2003, Psychological Medicine.

A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK

C. Twomey, A. Cieza, D. Baldwin, 2015, BMJ Open.

The side effect burden associated with drug treatment of panic disorder.

D. Baldwin, J. Birtwistle, 1998, The Journal of clinical psychiatry.

Structured relaxation in the treatment of akathisia: case series

D. Baldwin, L. Hansen, T. L’Allemand, 2010, European Neuropsychopharmacology.

The future of antidepressant pharmacotherapy.

D. Baldwin, C. Thompson, 2003, World psychiatry : official journal of the World Psychiatric Association.

Veterinary surgeons and suicide: a structured review of possible influences on increased risk

D. Baldwin, D. Bartram, D. J. Bartram, 2010, Veterinary Record.

and characteristics in a casualty population. Suicidal ideation as a presenting complaint. Associated diagnoses

D. James, D. Baldwin, R. Priest, 2013 .

Attempted suicide in west London, I. Rates across ethnic communities

D. Bhugra, D. Baldwin, M. Desai, 1999, Psychological Medicine.

Attempted suicide in west London, II. Inter-group comparisons

D. Bhugra, D. Baldwin, K. Jacob, 1999, Psychological Medicine.

Preferential consolidation of emotional reactivity during sleep: A systematic review and meta-analysis

D. Baldwin, B. Stuart, M. Henry, 2022, Frontiers in Behavioral Neuroscience.

Investigation of cortisol levels in patients with anxiety disorders: a structured review.

D. Baldwin, Hesham Y Elnazer, 2014, Current topics in behavioral neurosciences.

Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder

K. Mogg, B. Bradley, D. Baldwin, 2004, Psychopharmacology.

Veterinary surgeons and suicide: influences, opportunities and research directions

D. Baldwin, D. Bartram, 2008, Veterinary Record.

Mental health and wellbeing survey

D. Baldwin, D. Bartram, 2007, Veterinary Record.

Mental health and wellbeing survey

D. Baldwin, D. Bartram, 2007, Veterinary Record.

The role of serotonin in depression and anxiety

D. Baldwin, S. Rudge, 1995, International clinical psychopharmacology.

Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.

Dan J Stein, D. Baldwin, O. Dolberg, 2006, The Journal of clinical psychiatry.

Placebo-controlled studies in depression: necessary, ethical and feasible

H. Möller, H. Westenberg, S. Kasper, 2003, European Archives of Psychiatry and Clinical Neuroscience.

Pharmacological treatment of generalized anxiety disorder.

Matthew Garner, D. Baldwin, M. Garner, 2010, Current topics in behavioral neurosciences.

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran

M. Briley, D. Baldwin, R. Moreno, 2008, Human psychopharmacology.

Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine

D. Baldwin, C. Buis, K. Bridgman, 2006, Journal of psychopharmacology.

studydisorder : Randomised, placebo-controlled, double-blind Escitalopram and paroxetine in the treatment of generalised

D. Baldwin, Eli Mæhlum, Anna Karina, 2013 .

No psychiatry without psychopharmacology.

Paul J. Harrison, Klaus P. Ebmeier, D. Nutt, 2011, The British journal of psychiatry : the journal of mental science.

Clinical characteristics and unlicensed applications of licensed psychotropic drugs within a regional tertiary service for patients with affective disorders

D. Baldwin, N. Tiwari, 2018, Therapeutic advances in psychopharmacology.

Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients.

D. Baldwin, Robert Gordon, N. Tiwari, 2015, Current pharmaceutical design.

Off-label prescribing by psychiatrists

D. Baldwin, F. Lowe-Ponsford, 2000 .

The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide

N. Fineberg, D. Baldwin, A. Sahadevan, 2003, International journal of psychiatry in clinical practice.

Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?

D. Baldwin, Hugo Amaro, 2019, CNS Drugs.

A randomised pilot feasibility study of eye movement desensitisation and reprocessing recent traumatic episode protocol, to improve psychological recovery following intensive care admission for COVID-19

D. Baldwin, N. Pattison, M. Grocott, 2022, Journal of the Intensive Care Society.

Biological treatment of unipolar depressive disorders in the general practitioner's medical care: Guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP)

Gheorghe, D. Kupfer, H. Möller, 2008 .

Brief Communication: Differences Between Ethnic Groups in Demographic and Clinical Features of Patients Admitted and Assessed After Deliberate Self-Harm: A Retrospective Case-Note Study

D. Baldwin, R. Nair, K. Bhogal, 2006, The International journal of social psychiatry.

Psychiatric illness and resilience to adversity

D. Baldwin, 2016 .

Covid-19: doctors must take control of their wellbeing

D. Baldwin, Gemma Simons, 2020, BMJ.

Unlicensed applications of licensed psychotropic drugs in an intellectual disability clinical service: retrospective case-note study

D. Baldwin, Soumya Ghosh, A. Arulrajan, 2010, Journal of intellectual disabilities : JOID.

A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.

D. Baldwin, R. Abed, S. Buckingham, 1996, The Journal of clinical psychiatry.

Cross-Sectional Associations of Depressive Symptom Severity and Functioning with Health Service Use by Older People in Low-and-Middle Income Countries

C. Twomey, A. Cieza, M. Prince, 2015, International journal of environmental research and public health.

Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies

D. Baldwin, H. Fagan, E. Jones, 2022, CNS Drugs.

The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management

D. Baldwin, A. Montejo, L. Montejo, 2018, World psychiatry : official journal of the World Psychiatric Association.

Pregabalin for the treatment of generalized anxiety disorder: an update

D. Baldwin, V. Masdrakis, K. Ajel, 2013, Neuropsychiatric disease and treatment.

Generalised anxiety disorder

D. Baldwin, P. Tyrer, 2006, The Lancet.

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

J. A. Boer, D. Nutt, J. Davidson, 2005, Journal of psychopharmacology.

Evidence-based pharmacotherapy of Generalized Anxiety Disorder.

D. Baldwin, Claire Polkinghorn, 2005, The international journal of neuropsychopharmacology.

Impact of Antidepressant Drugs on Sexual Function and Satisfaction

D. Baldwin, C. Manson, Magda Nowak, 2015, CNS Drugs.

The Validity of the State-Trait Anxiety Inventory and the Brief Scale for Anxiety in an Inpatient Sample with Alcohol Use Disorder.

D. Baldwin, M. Schwandt, L. Leggio, 2021, Addiction.

Social functioning in depression: a review.

M B Keller, S Kasper, H. Möller, 2000, The Journal of clinical psychiatry.

A neurobiological framework of separation anxiety and related phenotypes

K. Domschke, D. Baldwin, B. Bandelow, 2020, European Neuropsychopharmacology.

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

J. Lieberman, J. Markowitz, S. Kanba, 2007, The international journal of neuropsychopharmacology.

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

Dan J Stein, H. Möller, G. Goodwin, 2011, European Archives of Psychiatry and Clinical Neuroscience.

THE NATURE AND RECURRENCE OF RBD ON PLACEBO

D. Baldwin, S. Montgomery, D. Montgomery, 1992, Clinical neuropharmacology.

Intermittent 3-day depressions and suicidal behaviour.

D. Baldwin, S. Montgomery, M. Green, 1989, Neuropsychobiology.

Efficacy of vortioxetine on the physical symptoms of major depressive disorder

D. Baldwin, I. Florea, M. C. Christensen, 2018, Journal of psychopharmacology.

Sexual side-effects of antidepressant and antipsychotic drugs

D. Baldwin, A. Mayers, 2003 .

Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy

A. Altamura, B. Dell’Osso, D. Baldwin, 2010, Human psychopharmacology.

Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy

A. Altamura, B. Dell’Osso, D. Baldwin, 2010, Human psychopharmacology.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression

H. Möller, G. Goodwin, S. Kasper, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Excitatory Amino Acids and Their Antagonists

P. Shizgal, S. Nieuwenhuis, Sarah L Parylak, 2015 .

Safety and Tolerability of Antidepressants

D. Baldwin, C. Manson, Robert Gordon, 2016 .

Do SSRIs or antidepressants in general increase suicidality?

Dan J Stein, H. Möller, G. Goodwin, 2008, European Archives of Psychiatry and Clinical Neuroscience.

WPA Section on Pharmacopsychiatry: consensus statement

D. Stein, G. Goodwin, S. Kasper, 2008 .

Pharmacological provocation and prevention of suicidal behaviour

D. Baldwin, 2000 .

Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature

D. Baldwin, J. D. den Boer, B. Emir, 2015, Journal of psychopharmacology.

Psychotropic Drugs and Sexual Dysfunction

D. Baldwin, 1995 .

An Atlas of Depression

D. Baldwin, J. Birtwistle, 2002 .

Personality: Neurobehavioural Foundation and Pharmacological Protocols

Stephanie A. Carmack, C. McDougle, D. Posey, 2014 .

Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder

D. Baldwin, A. Mayers, C. Buis, 2002, Expert review of neurotherapeutics.

Why do amitriptyline and dothiepin appear to be so dangerous in overdose?

D. Baldwin, S. Montgomery, M. Green, 1989, Acta psychiatrica Scandinavica. Supplementum.

Suicide in depressive disorders: a retrospective case-control study of 127 suicides.

D. Baldwin, J. Sinclair, L. Harriss, 2005, Journal of affective disorders.

The Wessex Recent In-Patient Suicide Study, 1

Michael J. Campbell, D. Baldwin, J. Sinclair, 2001, British Journal of Psychiatry.

The Wessex Recent In-Patient Suicide Study, 2

Michael J. Campbell, D. Baldwin, J. Sinclair, 2001, British Journal of Psychiatry.

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

A. Young, C. Pariante, A. Lingford-Hughes, 2017, Journal of psychopharmacology.

Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire

D. Baldwin, 2005 .

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

D. Stein, J. Davidson, D. Baldwin, 2006, Archives of general psychiatry.

Evidence-based Guidelines for Anxiety Disorders: Can They Improve Clinical Outcomes?

D. Baldwin, David S Baldwin, 2006, CNS Spectrums.

The economic consequences of social phobia.

D. Baldwin, M. Knapp, Anita Patel, 2002, Journal of affective disorders.

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

G. Lewis, J. Geddes, D. Baldwin, 2016, Health technology assessment.

British Journal of Psychiatry (1991), 159, 232â€”238 Assessment of suicide risk is an important aspect of psychiatricpractice, and the patient at risk of suicide evokes a high level of concern from psychiatric

D. James, D. Baldwin, C. Hawley, 2006 .

Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?

D. Baldwin, M. Garner, 2008 .

Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy

H. Möller, S. Kasper, G. Hasler, 2015, International journal of psychiatry in clinical practice.

Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review

D. Baldwin, V. Masdrakis, 2021, Therapeutic advances in psychopharmacology.

Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

Michael J. Campbell, M. Buxton, D. Baldwin, 2006, British Journal of Psychiatry.

Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

Michael J. Campbell, M. Buxton, D. Baldwin, 2006, British Journal of Psychiatry.

Sex and segregation: Staff attitudes explored

D. Baldwin, P. Thomas, M. Cole, 2003, International journal of psychiatry in clinical practice.

Structured review of the use of the Arizona sexual experiences scale in clinical settings

D. Baldwin, Hesham Y Elnazer, 2020, Human psychopharmacology.

Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants

D. Baldwin, M. Palazzo, V. Masdrakis, 2013, Depression research and treatment.

Sexual dysfunction associated with antidepressant drugs

D. Baldwin, 2004, Expert opinion on drug safety.

Depression and sexual dysfunction.

D. Baldwin, 2001, British medical bulletin.

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

I. Hindmarch, D. Baldwin, J. Cooper, 2006, International clinical psychopharmacology.

Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder

Yan-song Liu, D. Baldwin, R. Hou, 2019, Brain, Behavior, and Immunity.

The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis

D. Baldwin, L. Leggio, J. Sinclair, 2021, Neuroscience & Biobehavioral Reviews.

Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence

D. Baldwin, J. Sinclair, Celia J. Shiles, 2016, Drug Safety.

Hair cortisol concentration in anxiety disorders. Exploration of relationships with symptom severity and inflammatory markers.

D. Baldwin, L. Lau, Hesham Y Elnazer, 2020, Acta neuropsychiatrica.

Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study

C. Holmes, D. Baldwin, C. Osmond, 2017, Brain, Behavior, and Immunity.

Developing a European research network to address unmet needs in anxiety disorders

P. Zwanzger, S. Pallanti, D. Baldwin, 2013, Neuroscience & Biobehavioral Reviews.

Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder

Dan J Stein, D. Baldwin, F. Howells, 2018, Translational Psychiatry.

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

D. Baldwin, B. Batinić, I. Ristić, 2021, Frontiers in Psychiatry.

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

D. Nutt, D. Dijk, A. Krystal, 2019, Journal of psychopharmacology.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD

Dan J Stein, D. Rujescu, E. Hollander, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Health literacy and the pharmacological treatment of anxiety disorders: a systematic review

Dan J Stein, B. Dell’Osso, D. Baldwin, 2014, Human psychopharmacology.

First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia

S. Montgomery, D. Baldwin, 1995, International clinical psychopharmacology.

Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review.

D. Baldwin, C. Karner, S. Barton, 2014, Health technology assessment.

The World Federation of Socleties of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania

Charles Bowden, Hans-Jürgen Möller, Eduard Vieta, 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction.

S. Montgomery, D. Baldwin, A. Riley, 2002, Journal of affective disorders.

Role of dopamine in schizophrenia and Parkinson's disease.

D. Baldwin, J. Birtwistle, J Birtwistle, 1998, British journal of nursing.

Prevalence, clinical correlates and IQ of suicidal ideation in drug naïve Chinese Han patients with major depressive disorder.

Jingping Zhao, D. Baldwin, Xiufeng Xu, 2019, Journal of affective disorders.

Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study

D. Baldwin, A. Sampson, Hesham Y Elnazer, 2021, International clinical psychopharmacology.

Treatment of Obsessive-Compulsive Disorder

D. Stein, D. Baldwin, J. Ipser, 2007, CNS Spectrums.

Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively

D. Baldwin, S. Chamberlain, 2021, CNS Drugs.

Antidepressant drugs and sexual dysfunction

D. Baldwin, T. Foong, 2013, British Journal of Psychiatry.

Antidepressants, withdrawal, and addiction; where are we now?

P. Cowen, D. Nutt, G. Goodwin, 2019, Journal of psychopharmacology.

Discontinuation symptoms in depression and anxiety disorders.

S. Montgomery, D. Baldwin, M. Lader, 2007, The international journal of neuropsychopharmacology.

Drugs to Treat Anxiety and Insomnia

D. Baldwin, N. Huneke, 2020, Seminars in Clinical Psychopharmacology.

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

D. Baldwin, H. Loft, I. Florea, 2012, International clinical psychopharmacology.

Escitalopram and paroxetine in the treatment of generalised anxiety disorder

D. Baldwin, Eli Mæhlum, A. Huusom, 2006, British Journal of Psychiatry.

Essential considerations when choosing a modern antidepressant

D. Baldwin, 2003, International journal of psychiatry in clinical practice.

Vortioxetine in the treatment of major depressive disorder

D. Baldwin, Venkatesh Ballagere Hanumanthaiah, 2015 .

Effects of antidepressant drugs on sexual function.

D. Baldwin, J. Birtwistle, Sally C Thomas, 1997, International journal of psychiatry in clinical practice.

Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets

D. Baldwin, R. Hou, M. Garner, 2017, CNS Drugs.

Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review

N. Fineberg, J. Grant, D. Baldwin, 2021, Neuroscience & Biobehavioral Reviews.

Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review

D. Baldwin, Hesham Y Elnazer, 2013, Acta Neuropsychiatrica.

Panic Disorder and Agoraphobia

K. Domschke, V. Starcevic, D. Baldwin, 2007 .

Yogic Breathing Instruction in Patients with Treatment-Resistant Generalized Anxiety Disorder: Pilot Study

D. Baldwin, M. Garner, N. Tiwari, 2019, International journal of yoga.

Utility of functioning in predicting costs of care for patients with mood and anxiety disorders: a prospective cohort study

C. Twomey, A. Cieza, D. Baldwin, 2017, International clinical psychopharmacology.

Attentional biases in patients with alcohol dependence: influence of coexisting psychopathology

D. Baldwin, M. Garner, J. Sinclair, 2016, Human psychopharmacology.

Manifesto for a European Anxiety Disorders Research Network

J. Vázquez-Barquero, A. Metspalu, N. Fineberg, 2010, European Neuropsychopharmacology.

Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670

D. Baldwin, K. Donaldson, John Hutchison, 2008, Journal of psychopharmacology.

Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.

D. Baldwin, S. Fehnel, S. Hogue, 2006, The Journal of clinical psychiatry.

The effect of attachment security priming and oxytocin on physiological responses to trauma films and subsequent intrusions.

K. Carnelley, D. Baldwin, M. Heinrichs, 2021, Behaviour research and therapy.

"Craving": exploring the components of the Desires for Alcohol Questionnaire (DAQ) and the relation to the severity of alcohol problems.

D. Baldwin, M. Garner, J. Sinclair, 2013, Journal of studies on alcohol and drugs.

Psychological interventions in the treatment of generalized anxiety disorder: a structured review

D. Baldwin, C. Ruini, F. Bolognesi, 2014 .

The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management

Dan J Stein, B. Rothbaum, M. Craske, 2021, World psychiatry : official journal of the World Psychiatric Association.

Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor–Davidson Resilience Scale

B. Rothbaum, D. Stein, J. Davidson, 2008, International clinical psychopharmacology.

Effects of exercise on obsessive-compulsive disorder symptoms: a systematic review and meta-analysis

N. Fineberg, D. Baldwin, K. Laws, 2022, International Journal of Psychiatry in Clinical Practice.

Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder

D. Baldwin, Ayman Abou-Aisha, 2019, Translational Medicine in CNS Drug Development.

Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder.

D. Baldwin, R. Hou, Xinyun Chen, 2018, Journal of affective disorders.

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo

D. Baldwin, K. Larsen, Satoshi Asakura, 2016, European Neuropsychopharmacology.

Manifesto for a European research network into obsessive-compulsive and related disorders

D. Stein, N. Fineberg, D. Denys, 2013, European Neuropsychopharmacology.

Overcoming barriers in the pharmacological treatment of anxiety disorders

D. Baldwin, Bilal Talat, R. Rafiq, 2013 .

A joint European and South African research network in anxiety disorders

Dan J Stein, D. Baldwin, 2012, Human psychopharmacology.

Untitled Page

D. Baldwin, David S. Baldwin, 2012 .

Pharmacological Treatment of Anxiety Disorders

D. Baldwin, Emma K. Brandish, 2014 .

Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?

D. Baldwin, E. Schweizer, Yikang Xu, 2012, European Neuropsychopharmacology.

How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database

Dan J Stein, D. Baldwin, O. Dolberg, 2009, Human psychopharmacology.

Evaluating psychological interventions in a novel experimental human model of anxiety

Marcus R. Munafò, Matthew Garner, Ben Ainsworth, 2015, Journal of psychiatric research.

The effect of focused attention and open monitoring meditation on attention network function in healthy volunteers

D. Baldwin, B. Ainsworth, M. Garner, 2013, Psychiatry Research.

A Criticism of the Practice of Prescribing Subtherapeutic Doses of Antidepressants for the Treatment of Depression

D. Baldwin, M. Lader, G. Beaumont, 1996 .

Optimizing outcomes in depression: focus on antidepressant compliance

R. Hirschfeld, K. Demyttenaere, D. Baldwin, 2002, International clinical psychopharmacology.

A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.

D. Baldwin, G. Nomikos, I. Florea, 2016, Journal of affective disorders.

Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of generalized anxiety disorder

D. Baldwin, C. Allgulander, S. Waldman, 2012 .

Evidence-based pharmacological treatment of generalized anxiety disorder.

D. Baldwin, C. Allgulander, S. Waldman, 2011, The international journal of neuropsychopharmacology.

The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?

D. Baldwin, N. Tiwari, 2009, CNS Spectrums.

Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies

D. Stein, D. Baldwin, F. Mandel, 2008, European Neuropsychopharmacology.

The separation of adult separation anxiety disorder

D. Baldwin, M. Abelli, S. Pini, 2016, CNS Spectrums.

Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo‐controlled trial of duloxetine

D. Baldwin, F. Bishop, M. Garner, 2016, Human psychopharmacology.

Antidepressants and their effect on sleep

D. Baldwin, A. Mayers, 2005, Human psychopharmacology.

Daytime intrusive thoughts and subjective insomnia symptoms

D. Baldwin, M. Garner, L. Baker, 2015, Psychiatry Research.

Moclobemide: a reversible inhibitor of monoamine oxidase type A.

D. Baldwin, S. Rudge, 1993, British journal of hospital medicine.

Modelling PTSD diagnosis using sleep, memory, and adrenergic metabolites: An exploratory machine‐learning study

D. Baldwin, M. Breen, K. Thomas, 2019, Human psychopharmacology.

A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials

B. Rothbaum, D. Stein, J. Davidson, 2013, Brain and behavior.

Suicidal Ideation as a Presenting Complaint

D. James, D. Baldwin, C. Hawley, 1991, British Journal of Psychiatry.

Inhalation of 7.5% Carbon Dioxide Increases Threat Processing in Humans

M. Munafo, A. Attwood, D. Baldwin, 2011, Neuropsychopharmacology.

Symptoms of fatigue and sleepiness in major depressive disorder.

George I Papakostas, D. Baldwin, G. Papakostas, 2006, The Journal of clinical psychiatry.

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology

G. Fricchione, G. Northoff, D. Baldwin, 2023, Journal of psychopharmacology.

Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression.

D. Baldwin, B. Batinić, G. Opacic, 2017, Psychiatria Danubina.

Feasibility, acceptability and practicality of transcranial stimulation in obsessive compulsive symptoms (FEATSOCS): A randomised controlled crossover trial.

Megan V. Smith, N. Fineberg, Kabir Garg, 2023, Comprehensive psychiatry.

Clinically relevant drug interactions in anxiety disorders

D. Baldwin, B. Bandelow, E. Spina, 2012, Human psychopharmacology.

Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment.

M. Trivedi, D. Nutt, Y. Lecrubier, 2006, The Journal of clinical psychiatry.

Non-pharmacological treatment

K. Domschke, D. Baldwin, B. Bandelow, 2013 .

Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders

H. Möller, D. Stein, G. Goodwin, 2012, European Archives of Psychiatry and Clinical Neuroscience.

Which antidepressants have demonstrated superior efficacy? A review of the evidence

Naomi A. Fineberg, Hans-Jürgen Möller, Siegfried Kasper, 2007, International clinical psychopharmacology.

BETTER-Project: Web Accessibility for Persons with Mental Disorders

Shadi Abou-Zahra, Renaldo Bernard, Carla Sabariego, 2015, HCI.

Quantifying subjective assessment of sleep and life‐quality in antidepressant‐treated depressed patients

D. Baldwin, J. C. van Hooff, A. Mayers, 2003, Human psychopharmacology.

Online P&A March 27.indd

D. Baldwin, D. Bartram, 2010 .

A cross-sectional study of mental health and well-being and their associations in the UK veterinary profession

D. Baldwin, G. Yadegarfar, D. Bartram, 2009, Social Psychiatry and Psychiatric Epidemiology.

Suicide in schizophrenia: a retrospective case-control study of 51 suicides.

D. Baldwin, J. Sinclair, M. Mullee, 2004, Schizophrenia bulletin.

Depression and Personality: Conceptual and Clinical Challenges

D. Baldwin, 2007, British Journal of Psychiatry.

Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls.

D. Baldwin, I. Aslan, 2020, Journal of affective disorders.

Altered executive control network resting-state connectivity in social anxiety disorder

Katharina Domschke, Dan J Stein, Jonathan Ipser, 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Identity in recovery from problematic alcohol use: A qualitative study of online mutual aid.

D. Baldwin, K. Canvin, J. Sinclair, 2017, Drug and alcohol dependence.

Pharmacological treatment of social phobia

D. Baldwin, K. Bhogal, 2007 .

Attentional biases in clinical populations with alcohol use disorders: is co‐morbidity ignored?

D. Baldwin, M. Garner, J. Sinclair, 2010, Human psychopharmacology.

Course and outcome of patients with alcohol use disorders following an alcohol intervention during hospital attendance: mixed method study

D. Baldwin, J. Sinclair, Sophia E Chambers, 2020, BJPsych Open.

Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder

D. Baldwin, R. El-Khayat, 1998, Journal of psychopharmacology.

ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder

Y. Lecrubier, S. Kasper, J. M. Ree, 2004, European Neuropsychopharmacology.

Lithium and sexual dysfunction: an under‐researched area

D. Baldwin, A. Sampson, Hesham Y. Elnazer, 2015, Human psychopharmacology.

Easing the Burden of Panic Disorder: Comorbidity, Diagnosis, and Implications for Treatment

D. Baldwin, David Baldwin, 2005, CNS Spectrums.

Early effects of duloxetine on emotion recognition in healthy volunteers

M. Munafo, I. Penton-Voak, D. Baldwin, 2015, Journal of psychopharmacology.

Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period

Dan J Stein, D. Baldwin, F. Howells, 2021, Schizophrenia Research.

Genetic mechanisms of electroconvulsive therapy response in depression

Dan J Stein, K. Domschke, D. Baldwin, 2016, Human psychopharmacology.

Quality of case reports of adverse drug reactions with psychotropic drugs: a 25‐year review

D. Baldwin, A. Mayers, Bilal Talat, 2013, Human psychopharmacology.

The relationship between sleep disturbance and depression

D. Baldwin, A. Mayers, David S Baldwin, 2006, International journal of psychiatry in clinical practice.

The relationship between sleep disturbance and depression: A review

D. Baldwin, A. Mayers, 2006 .

Non-prescribed use of gabapentinoids: Mechanisms, predisposing factors, associated hazards and clinical management

D. Baldwin, V. Masdrakis, 2022, European Neuropsychopharmacology.

Why we need more research into the placebo response in psychiatry

D. Baldwin, M. Garner, N. J. van der Wee, 2020, Psychological Medicine.

17 – Neurotic, stress-related and somatoform disorders

D. Baldwin, Janeane L. Walker, M. Sharpe, 2010 .

Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders

D. Baldwin, 2006, International journal of psychiatry in clinical practice.

Anxiety in asthma: a systematic review and meta-analysis

D. Baldwin, R. Hou, G. Ye, 2021, Psychological Medicine.

Subjective sleep, depression and anxiety: inter‐relationships in a non‐clinical sample

D. Baldwin, A. Mayers, Andrew G. Mayers, 2009, Human psychopharmacology.

Assessing subjective sleep reports in the first‐degree relatives of antidepressant‐treated depressed outpatients

D. Baldwin, J. C. van Hooff, A. Mayers, 2003, Human psychopharmacology.

Antidepressants for insomnia in adults.

A. Malizia, Sue J. Wilson, D. Baldwin, 2018, The Cochrane database of systematic reviews.

On predicting the response to antidepressant treatment

D. Baldwin, F. Bolognesi, 2012, Human psychopharmacology.

7.5% carbon dioxide inhalation increases threat processing in humans

M. Munafo, A. Attwood, D. Baldwin, 2011 .

Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders service.

D. Baldwin, M. Garner, H. Graystone, 2009, Journal of affective disorders.

Recent advances in antidepressant drugs.

D. Baldwin, R. Priest, N. Smeyatsky, 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Defensive eye-blink startle responses in a human experimental model of anxiety

D. Baldwin, M. Garner, S. Bamford, 2014, Journal of psychopharmacology.

The importance of long-term tolerability in achieving recovery

D. Baldwin, 2006, International journal of psychiatry in clinical practice.

Does previous experience of antidepressants form the expectations necessary for a placebo response?

D. Baldwin, N. Huneke, 2015, The British journal of psychiatry : the journal of mental science.

Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts

D. Baldwin, S. Montgomery, M. Green, 2005, European Archives of Psychiatry and Clinical Neuroscience.

Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study

D. Baldwin, M. Garner, A. Darekar, 2019, bioRxiv.

A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment

D. Baldwin, C. Hawley, K. Mellors, 2001, Journal of psychopharmacology.

Paroxetine in social phobia/social anxiety disorder

D. Stein, J. Bobes, D. Baldwin, 1999, British Journal of Psychiatry.

Pharmacological treatment of social anxiety disorder.

D. Baldwin, V. Masdrakis, D. Turic, 2013, Modern trends in pharmacopsychiatry.

Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study

S. Montgomery, D. Baldwin, M. Green, 2014, International clinical psychopharmacology.

Prevention of suicide by clozapine in mental disorders: systematic review

D. Baldwin, V. Masdrakis, 2023, European Neuropsychopharmacology.

Oxytocin receptor gene variation, behavioural inhibition, and adult separation anxiety: Role in complicated grief

K. Domschke, C. Martini, D. Baldwin, 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Where is the room for improvement in the drug treatment of depression and anxiety?

D. Baldwin, 2011, Human psychopharmacology.

Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study

K. Domschke, B. Dell’Osso, D. Baldwin, 2021, CNS Spectrums.

On ‘cognitive dysfunction’ as a novel target for antidepressant treatment

D. Baldwin, B. Impey, 2013, Human psychopharmacology.

Can we distinguish anxiety from depression?

R. Hirschfeld, S. Kasper, D. Baldwin, 2002, Psychopharmacology bulletin.

Selective serotonin re-uptake inhibitors in anxiety disorders: room for improvement

D. Baldwin, J. Birtwistle, 2000 .

The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder.

A. Siracusano, D. Baldwin, G. Cassano, 2014, Journal of anxiety disorders.

Plasma‐Level Response Relationships with Fluoxetine and Zimelidine

N. Fineberg, D. Baldwin, S. Montgomery, 1990, Clinical neuropharmacology.

Impaired identification of fearful faces in Generalised Social Phobia.

K. Mogg, B. Bradley, D. Baldwin, 2009, Journal of affective disorders.

Utility of the Health of the Nation Outcome Scales (HoNOS) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems: Historical Cohort Study

Robert Stewart, Alarcos Cieza, Jayati Das-Munshi, 2016, PloS one.

Nation Outcome Scales ( HoNOS ) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems : Historical Cohort Study

R. Stewart, C. Twomey, A. Cieza, 2016 .

Diverse predictors of treatment response to active medication and placebo in gambling disorder.

J. Grant, D. Baldwin, S. Chamberlain, 2021, Journal of psychiatric research.

Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1).

E. Hollander, N. Fineberg, J. Grant, 2022, Comprehensive Psychiatry.

Inter-rater reliability of the Hamilton Depression Rating Scale as a diagnostic and outcome measure of depression in primary care.

R. Morriss, D. Baldwin, M. Leese, 2008, Journal of affective disorders.

Room for improvement in the pharmacological treatment of anxiety disorders.

D. Baldwin, 2008, Current pharmaceutical design.

Further validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in the UK veterinary profession: Rasch analysis

D. Baldwin, J. Sinclair, D. Bartram, 2013, Quality of Life Research.

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

D. Baldwin, H. Loft, M. Dragheim, 2012, European Neuropsychopharmacology.

Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function

M. Munafo, A. Attwood, D. Baldwin, 2012, Psychopharmacology.

Clinical evaluation of psychotropic drugs

D. Baldwin, 2004 .

On assessing potential efficacy for vortioxetine in generalized anxiety disorder

D. Nutt, D. Baldwin, 2012, European Neuropsychopharmacology.

Superiority of escitalopram to paroxetine in the treatment of depression

Siegfried Kasper, Sara Larsson Lönn, S. Kasper, 2009, European Neuropsychopharmacology.

Anxiety disorders, post-traumatic stress disorder, and obsessive–compulsive disorder

D. Baldwin, Emma K. Brandish, Robert Gordon, 2016, Medicine.

Preferential Consolidation of Emotional Memory During Sleep: A Meta-Analysis

D. Baldwin, K. Thomas, Elaina Bolinger, 2019, Front. Psychol..

The relationship of separation anxiety with the age of onset of panic disorder.

K. Domschke, D. Baldwin, B. Bandelow, 2023, Early intervention in psychiatry.

P.4.b.015 Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder and obsessive-compulsive disorder?

A. Altamura, B. Dell’Osso, D. Baldwin, 2016, European Neuropsychopharmacology.

Suicide in psychiatric in-patients

D. Baldwin, A. Mayers, R. Elgie, 2003 .

Discharging psychiatric patients from hospital

D. Baldwin, J. Sinclair, 2002 .

Adult separation anxiety disorder: accepted but little understood

D. Baldwin, J. Rochester, 2015, Human psychopharmacology.

Guidelines for the investigation of efficacy in social anxiety disorder.ECNP Consensus Meeting

D. Stein, Y. Lecrubier, S. Kasper, 2004 .

Anxiety disorders: does one treatment fit all?

D. Baldwin, 2004, International journal of psychiatry in clinical practice.

HOW WELL ARE ANXIETY DISORDERS MANAGED ? GENERALISED ANXIETY DISORDER

D. Baldwin, 2004 .

The Effect of Prefrontal Transcranial Direct Current Stimulation on Attention Network Function in Healthy Volunteers

Matthew Garner, D. Baldwin, M. Garner, 2018, Neuromodulation : journal of the International Neuromodulation Society.

Authors’ Reply to Ulrich: Comment on ‘Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively’

S. Chamberlain, D. Baldwin, 2021, CNS Drugs.

Variation in clinical care associated with weekend admission and discharge in psychiatric in-patient units: retrospective case-note review

D. Baldwin, M. Crawford, A. Quirk, 2020, BJPsych Open.

Antidepressants for insomnia

A. Malizia, Sue J. Wilson, D. Baldwin, 2013 .

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

D. Baldwin, I. Florea, T. Hansen, 2012, Current medical research and opinion.

Comprehensive treatment of social anxiety disorder

D. Baldwin, 2000, European Neuropsychopharmacology.

The tolerability of venlafaxine

D. Baldwin, J. Sinclair, J. Birtwistle, 1998 .

Sexual assault on wards: Staff actions and reactions

D. Baldwin, P. Thomas, M. Cole, 2003, International journal of psychiatry in clinical practice.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Hans-Jürgen Möller, Siegfried Kasper, Eric Hollander, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Tolerability and safety of citalopram.

D. Baldwin, F. Johnson, 1995 .

5‐HT Reuptake Inhibitors, Tricyclic Antidepressants and Suicidal Behaviour

D. Baldwin, S. Montgomery, D. Montgomery, 1991, International clinical psychopharmacology.

Focus on social functioning in depression.

M. Keller, R. Hirschfeld, S. Kasper, 1998, International journal of psychiatry in clinical practice.

Agomelatine improves symptoms of generalised anxiety disorder

D. Baldwin, Antonio T Lopes, 2009, Evidence-Based Mental Health.

Lamotrigine delays mood episodes in recently depressed bipolar I patients

J. Calabrese, K. Behnke, G. Sachs, 2002, European Neuropsychopharmacology.

The influence of comorbid anxiety disorders on outcome in major depressive disorder

D. Baldwin, Antonio T Lopes, 2009 .

Separation Anxiety and Measures of Suicide Risk Among Patients With Mood and Anxiety Disorders.

K. Domschke, C. Martini, D. Baldwin, 2021, Journal of Clinical Psychiatry.

Could improved recognition and treatment of anxiety disorders lead to a reduction in suicide?

D. Baldwin, V. Masdrakis, Sofia Konstantopoulou, 2023, Human psychopharmacology.

The generalized anxiety spectrum: prevalence, onset, course and outcome

A. Gamma, D. Baldwin, J. Angst, 2009, European Archives of Psychiatry and Clinical Neuroscience.

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.

D. Baldwin, R. Lane, D. Baldwin, 1997, Journal of clinical psychopharmacology.

How effective are current drug treatments for anxiety disorders, and how could they be improved?

D. Baldwin, M. Garner, 2008 .

HEROIN ADDICTION

T. Robbins, G. Remington, L. Wilkinson, 2010 .

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

J. Lieberman, J. Markowitz, S. Kanba, 2007, The international journal of neuropsychopharmacology.

The effect of focused attention and open monitoring meditation on attention network function in healthy volunteers

D. Baldwin, B. Ainsworth, M. Garner, 2013, Psychiatry Research.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

H. Möller, E. Hollander, D. Stein, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

J. A. Boer, D. Nutt, J. Davidson, 2005, Journal of psychopharmacology.

Clinical experience with paroxetine in social anxiety disorder

D. Baldwin, 2000, International Clinical Psychopharmacology.

Agomelatine in the treatment of mood and anxiety disorders.

D. Baldwin, Antonio T Lopes, 2010, British journal of hospital medicine.

Clinically relevant drug interactions in anxiety disorders

D. Baldwin, B. Bandelow, E. Spina, 2012, Human psychopharmacology.

The Asian Cultural Identity Schedule: an investigation of culture and deliberate self‐harm

D. Bhugra, D. Baldwin, K. Bhui, 1999 .

On reducing the duration of untreated illness in unipolar depression

D. Baldwin, 2011, Human psychopharmacology.